Complexos de metais de transição: aplicações no tratamento e diagnóstico da doença de Alzheimer
Resumen
Currently there are about 35.6 million people diagnosed with Alzheimer's
disease (AD) in the world, and it is expected that this number will double by 2050.
Causes of Alzheimer's disease are not yet known, but their symptoms are
characterized the decline of cognitive function result of overactivity of the enzyme
acetylcholinesterase (AChE); and accumulation of β-amyloid peptide (β-A) in the
brain of patients. Therefore it is important to the development of drugs that act on the
two problems of AD; cognitive decline (inhibition of AChE activity) and the
identification of fibrillar aggregates of β-A (creation of new probes). For this purpose
have been prepared and tested a series of luminescent complex; cis-[Ru(phen)2(4-
ImAC)]PF6, cis-[Ru(phen)2(4-ImAAc)]PF6, cis-[Ru(phen)2(2-Apy)](PF6)2, where phen
= 1,10-phenanthroline, ImAA = 4-imidazole acetic acid, ImAC = 4-imidazole
carboxylic acid and Apy = 2-aminopyridine. The ruthenium complexes were
synthesized, where its structural elucidation and purity were checked by NMR H1
spectroscopy and by microanalysis. The compounds are soluble in aqueous
solutions and exhibit an intense and broad absorption and emission in the visible
region. The complexes have relatively long life with 1 the order of 100 ns. The
complexes showed moderate inhibition against the enzyme AChE, with an IC50 of
about 10-20 μmol.L-1. From the images from confocal microscopy was possible to
make the location of the complex inside the cells by luminescent emission, where the
imidazole compounds were located specifically in the cytoplasmic portion of the cell,
unlike the complex with aminopyridine, which was distributed homogeneously
throughout cellular portion. It was possible to identify the formation of fibers from
measurements of emission of the luminescent complex, since these complexes have
intensity of luminescence variable with different types of Aβ aggregation. The fibrils
were also confirmed by fluorescence microscopy emission lifetime. From the results
of the complexes exhibit high pharmacological potential to the treatment of AD since
they can be used in diagnosis (identification of the fibrils) and in the treatment of AD
(AChE inhibition).
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Níveis de ADAM10 no líquido cefalorraquidiano e soro de indivíduos com doença de Alzheimer
Peron, Rafaela Cardoso (Universidade Federal de São Carlos, UFSCar, Programa de Pós-Graduação em Gerontologia - PPGGero, Câmpus São Carlos, 12/11/2018)Researchers have pointed out that the identification of ADAM10 as a biomarker can be an important tool to aid in the clinical diagnosis of AD. The proposal of ADAM10 as a biomarker occurs because it is involved in different ... -
Padronização de um método alternativo para diferenciação de células de neuroblastoma utilizando matriz extracelular rica em laminina para avaliação de ADAM10 e IDE em meios de cultivo hiperglicêmico e normoglicêmico
Grigoli, Marina Mantellatto (Universidade Federal de São Carlos, UFSCar, Programa de Pós-Graduação em Gerontologia - PPGGero, Câmpus São Carlos, 29/09/2023)Alzheimer’s disease (AD) is a gradual and progressive neurodegenerative disease characterized by cortical atrophy predominantly in the medial temporal lobe and, microscopically, by extensive neuronal losses and deposits ... -
Biomarcadores sanguíneos para a doença de Alzheimer : avaliação da expressão gênica da ADAM10 e de micro- RNAs
Moralles, Patricia Regina Manzine (Universidade Federal de São Carlos, UFSCar, Programa Interinstitucional de Pós-Graduação em Ciências Fisiológicas - PIPGCF, Câmpus São Carlos, 11/03/2016)ADAM10 is an-secretase that cleaves APP in the non-amyloidogenic pathway, thereby inhibiting -amyloid peptide (A ) production in Alzheimer´s disease (AD). Studies have shown decreased ADAM10 platelet levels in AD patients ...